Jim Cramer recently discussed McKesson Corporation (NYSE:MCK), a major healthcare services provider in America. Despite regulatory challenges, the stock has gained 26% year-to-date. Cramer believes the company’s strong earnings reports and dividend increases have contributed to its performance. He mentioned McKesson’s potential amidst government actions to cut drug costs.

McKesson reported a strong quarter with a top-line miss but a significant earnings beat. Cramer believes the company’s performance sparked a rally in the stock. However, concerns arose when Politico reported President Trump’s plan to adopt Most-Favored-Nation pricing for Medicare. This news impacted drug distributors like McKesson.

While McKesson shows promise as an investment, some believe that certain AI stocks offer greater potential for higher returns with limited downside risk. Investors interested in AI stocks benefiting from Trump tariffs and onshoring can explore a free report on the best short-term AI stock.

Read more at Yahoo Finance: If It Was Down, I’d Say “Fill Her Up,” Says Jim Cramer